Home โบ Osteosarcoma
Osteosarcoma clinical trials recruiting in the U.S.
52 studies for Osteosarcoma are recruiting participants at sites across the United States.
Cities with the most studies
- St. Louis, MO10 studies
- Memphis, TN10 studies
- Atlanta, GA10 studies
- Boston, MA9 studies
- Houston, TX9 studies
- Birmingham, AL7 studies
- Cincinnati, OH7 studies
- Mountain View, CA7 studies
- Los Angeles, CA7 studies
- Chicago, IL7 studies
- Dallas, TX6 studies
- Tampa, FL6 studies
- New York City, NY6 studies
- Washington, DC6 studies
- Philadelphia, PA6 studies
- Aurora, CO6 studies
- Durham, NC5 studies
- Honolulu, HI5 studies
- Milwaukee, WI5 studies
- The Bronx, NY5 studies
- Seattle, WA5 studies
- Charleston, SC4 studies
- Gainesville, FL4 studies
- Oakland, CA4 studies
- Orlando, FL4 studies
- Salt Lake City, UT4 studies
- Harrisburg, PA4 studies
- Clifton, NJ4 studies
- Columbus, OH4 studies
- Cleveland, OH4 studies
- Queens, NY4 studies
- Baltimore, MD4 studies
- Greenburgh, NY4 studies
- Portland, OR4 studies
- San Francisco, CA4 studies
- Nashville, TN3 studies
- Detroit, MI3 studies
- Richmond, VA3 studies
- San Diego, CA3 studies
- St. Petersburg, FL3 studies
By state
- Alabama7 studies
- Arizona4 studies
- Arkansas3 studies
- California17 studies
- Colorado6 studies
- Connecticut4 studies
- District of Columbia5 studies
- Florida10 studies
- Georgia10 studies
- Hawaii5 studies
- Illinois7 studies
- Louisiana3 studies
- Maryland5 studies
- Massachusetts9 studies
- Michigan6 studies
- Minnesota3 studies
- Missouri10 studies
- New Jersey6 studies
- New York11 studies
- North Carolina6 studies
- Ohio13 studies
- Oklahoma3 studies
- Oregon4 studies
- Pennsylvania9 studies
- Rhode Island3 studies
- South Carolina4 studies
- Tennessee12 studies
- Texas12 studies
- Utah4 studies
- Virginia3 studies
- Washington5 studies
- Wisconsin7 studies
Recently updated studies
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RecruitingPhase 1/2
Up to age 30 ยท All sexes ยท Updated Nov 12, 2026 ยท NCT06541262Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
RecruitingPhase 2
Ages 12 to 39 ยท All sexes ยท Updated Nov 12, 2026 ยท NCT04616560Safety and Feasibility of Intraoperative Visualization With Cytalux in Children
RecruitingPhase 1
Ages 6 to 17 ยท All sexes ยท Updated Nov 12, 2026 ยท NCT06235125Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
RecruitingPhase 1
Ages 12 to 50 ยท All sexes ยท Updated Nov 10, 2026 ยท NCT03093909The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma
RecruitingPhase 2
Ages 7 to 22 ยท All sexes ยท Updated Nov 4, 2026 ยท NCT07560826Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma
RecruitingPhase 2
Up to age 21 ยท All sexes ยท Updated Nov 3, 2026 ยท NCT07428993Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RecruitingPhase 1
7 Months โ 21 Years ยท All sexes ยท Updated Oct 27, 2026 ยท NCT02508038AOH1996 for the Treatment of Refractory Solid Tumors
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Oct 20, 2026 ยท NCT05227326Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
RecruitingPhase 1
Ages 1 to 30 ยท All sexes ยท Updated Oct 19, 2026 ยท NCT07144254XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Oct 13, 2026 ยท NCT06571734Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
RecruitingPhase 1
12 Months โ 20 Years ยท All sexes ยท Updated Oct 8, 2026 ยท NCT02013336Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
RecruitingPhase 1/2
Ages 12 and older ยท All sexes ยท Updated Oct 7, 2026 ยท NCT05588648Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
RecruitingPhase 2
Ages 12 and older ยท All sexes ยท Updated Oct 6, 2026 ยท NCT05019703Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
RecruitingPhase 2
Ages 0 to 50 ยท All sexes ยท Updated Oct 6, 2026 ยท NCT07321912Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma
RecruitingPhase 1
Up to age 50 ยท All sexes ยท Updated Sep 30, 2026 ยท NCT06492954Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma
RecruitingPhase 1/2
Ages 12 to 40 ยท All sexes ยท Updated Sep 3, 2026 ยท NCT07725380Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
RecruitingPhase 1/2
Up to age 26 ยท All sexes ยท Updated Sep 3, 2026 ยท NCT06465199Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
RecruitingPhase 1
Ages 5 to 40 ยท All sexes ยท Updated Sep 3, 2026 ยท NCT06156410Clinical Orthopaedic Data Bank (Acute and Chronic)
RecruitingObservational study
All ages ยท All sexes ยท Updated Sep 3, 2026 ยท NCT00411060Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial
RecruitingPhase 1
Ages 1 to 75 ยท All sexes ยท Updated Sep 1, 2026 ยท NCT07227571Losartan + Sunitinib in Treatment of Osteosarcoma
RecruitingPhase 1
Ages 10 and older ยท All sexes ยท Updated Sep 1, 2026 ยท NCT03900793Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RecruitingPhase 1/2
12 Months โ 30 Years ยท All sexes ยท Updated Aug 25, 2026 ยท NCT04851119Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
RecruitingPhase 3
Up to age 50 ยท All sexes ยท Updated Aug 25, 2026 ยท NCT05235165Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma
Recruiting
All ages ยท All sexes ยท Updated Aug 21, 2026 ยท NCT07514819SPEARHEAD-3 Pediatric Study
RecruitingPhase 1/2
Ages 2 to 21 ยท All sexes ยท Updated Aug 11, 2026 ยท NCT05642455From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.